Nonseminomatous germ cell tumors (NSGCT) are curable, even with unresectable metastatic disease.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Clinical Genitourinary Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers.J Clin Oncol. 1997; 15: 594-603
- Late relapses of germ cell malignancies: incidence, management, and prognosis.J Clin Oncol. 2006; 24: 5503-5511
- Clinical outcome and predictors of survival in late relapse of germ cell tumor.J Clin Oncol. 2008; 26: 5524-5529
- Update on late relapse of germ cell tumor: a clinical and molecular analysis.J Clin Oncol. 2003; 21: 113-122
- Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy.J Clin Oncol. 2005; 23: 6999-7004
- High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.N Engl J Med. 2007; 357: 340-348
- Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial.J Clin Oncol. 2012; 30: 800-805
- High dose chemotherapy as salvage treatment for unresectable late relapse germ cell tumors.J Urol. 2010; 184: 168-173
Published online: March 12, 2016
Accepted: March 7, 2016
Received: February 22, 2016
© 2016 Elsevier Inc. All rights reserved.